Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 251

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 251
---
 of three years. The compensation expense for the year ended December 31, 2024, was $53 (2023 – $192 and 2022 – $69) recognized over the vesting period. Option activity for the year ended December 31, 2024, 2023, and 2022 was as follows:
 
Summary of number and weighted average exercise prices of deferred shares units
 
                                          Stock options          Weighted average exercise price in $CAD    
------------------------------------------------------------------------------------------------------------
                                         #                                                                 $
Balance – January 1, 2022                          70,572                                           23.73   
Granted                                            10,620                                           21.61   
Exercised                                         (12,917   )                                        6.36   
Cancelled / Forfeited                              (3,540   )                                       27.12   
Balance –December 31, 2022                         64,735                                           28.37   
Granted                                            21,712                                           25.85   
Exercised                                          (1,416   )                                       11.86   
Cancelled / Forfeited                             (10,660   )                                       25.00   
Balance – December 31, 2023                        74,371                                           28.40   
Granted - Replacement options (note 5)             12,949                                           50.65   
Cancelled / Forfeited                             (11,296   )                                       25.71   
Balance – December 31, 2024                        76,024                                           25.77   
 
Concurrent with the Transaction described in Note 1, Business Overview, on June 3, 2024, each outstanding stock option was reissued to reflect the exchange rate of the Company’s common shares. Accordingly, all quantities and prices in these consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the share exchange and related adjustments.
 
 
F-35
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 

19.    Expenses
      by nature
---------------
  Summary of expense by nature
 
                                           December 31,                                            
                                       2024                 2023                 2022              
                                           $                    $                                 $
Inventory expensed during the year              4,432